Cited by 1,627PI3K/AKT/mTOR signaling in cancerHER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

The DOI matches its Crossref record; 20 of the 22 references it cites were found in a registry or an index.

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Open access

Berns, Katrien, Horlings, Hugo M., Hennessy, Bryan T., Madiredjo, Mandy, Hijmans, E. Marielle, Beelen, Karin, Linn, Sabine C., Gonzalez-Angulo, Ana Maria, Stemke-Hale, Katherine, Hauptmann, Michael, Beijersbergen, Roderick L., Mills, Gordon B., van de Vijver, Marc J., Bernards, René·2007·Cancer Cell

DOI 10.1016/j.ccr.2007.08.030

Open this paper in CoChat — free account Open PDF

Abstract

A large-scale RNA interference screen to discover genes involved in trastuzumab resistance in breast cancer identified only PTEN as a modulator of drug sensitivity. Oncogenic mutants of PIK3CA (activator of the same pathway and frequently mutated in breast cancer) also conferred resistance to trastuzumab in cell culture. In a cohort of 55 breast cancer patients, activation of the PI3K pathway, as judged by the presence of oncogenic PIK3CA mutations or low PTEN expression, was associated with poor prognosis after trastuzumab therapy, and the combined analysis of PTEN and PIK3CA identified twice as many patients at increased risk for progression compared to PTEN alone. Thus, assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to respond to trastuzumab-based therapy.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2007.08.030

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C. L., Donoho, G. P., Briggs, S., Robbins, C. M., Hostetter, G. H., Boguslawski, S. J., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,322
A large-scale RNAi screen in human cells identifies new components of the p53 pathway
Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., Kerkhoven, R. M., Madiredjo, M., Nijkamp, W., Weigelt, B., et al. (2004) · Nature Cell Biology · doi:10.1038/nature02371 · Cited by 1,080
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886
PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma
Saal, L. H., Holm, K., Maurer, M. S., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., MANSUKHANI, M. M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 877

Show all 22 references

Sorted by citations

Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H.-L. M., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,785
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 2,045
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., José, V., Fumagalli, D., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,254
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,268
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobágyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,163
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J. M., & Swain, S. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2656 · Cited by 1,170
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,060
The ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3309 · Cited by 1,031
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956
Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis
Wei, C., Yang, C., Wang, S., Shi, D., Zhang, C., Lin, X., Liu, Q., Dou, R., & Xiong, B. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0976-4 · Cited by 833
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Junttila, T. T., Akita, R. W., Parsons, K. L., Fields, C. T., Phillips, G. D. L., Friedman, L. S., Sampath, D., & Sliwkowski, M. X. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.020 · Cited by 848
The PI3K/AKT Pathway as a Target for Cancer Treatment
Mayer, I. A., & Arteaga, C. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 833
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C., Khan, F. U., Ihsan, A. U., & Zhang, J. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 818
The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer
Folkes, A. J., Ahmadi, K., ALDERTON, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 756
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Krop, I. E., Kim, S., González-Martı́n, A., LoRusso, P. M., Ferrero, J.-., Smitt, M. C., Yu, R., Leung, A. C. F., & Wildiers, H. P. M. W. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70178-0 · Cited by 726
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
Engelman, J. A., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 706
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Bendell, J. C., Rodon, J. A., Burris, H. A., de Jonge, M. J. A., Verweij, J., Birle, D. C., Demanse, D., Buck, S. S. D., Ru, Q. C., Peters, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 703
Analysis of PTEN , BRAF , and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
Deng, N., Goh, L. K., Wang, H., Das, K., Tao, J., Tan, I. B., Zhang, S., Lee, M., Wu, J., Lim, K. H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301839 · Cited by 645
Targeting the mTOR Signaling Network for Cancer Therapy
Meric‐Bernstam, F., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0766 · Cited by 640
Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways
Eroles, P., Bosch, A., Fidalgo, J. A. P., & Lluch, A. M. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.005 · Cited by 678
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
Vu, T. T., & Claret, F. X. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00062 · Cited by 636
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Uribe, M. L., Marrocco, I., & Yarden, Y. (2021) · Cancers · doi:10.3390/cancers13112748 · Cited by 604
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Roock, W. D., de Vriendt, V., Normanno, N., Ciardiello, F., & Tejpar, S. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70209-6 · Cited by 626
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
Körkaya, H., Paulson, A. K., Iovino, F., & Wicha, M. S. (2008) · Oncogene · doi:10.1038/onc.2008.207 · Cited by 557
Enabling personalized cancer medicine through analysis of gene-expression patterns
Veer, L. V. ‘., & Bernards, R. (2008) · Nature · doi:10.1038/nature06915 · Cited by 558
Highly parallel identification of essential genes in cancer cells
Luo, B., Cheung, H. W., Subramanian, A., Sharifnia, T., Okamoto, M., Yang, X., Hinkle, G., Boehm, J. S., Beroukhim, R., Weir, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810485105 · Cited by 541
Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population
Körkaya, H., Kim, G.-I., Davis, A., Malik, F. A., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R. C., Paulson, A. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.014 · Cited by 546
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Wagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B. S., DeFelice, M. T., Pochanard, P., Ducar, M. D., Hummelen, P. V., MacConaill, L. E., Hahn, W. C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0184 · Cited by 529
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodríguez, O., Guzmán, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 541
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515
Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling
Korkaya, H., Paulson, A., Charafe-Jauffret, E., Ginestier, C., Brown, M., Dutcher, J., Clouthier, S. G., & Wicha, M. S. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000121 · Cited by 523
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
Guix, M., Faber, A. C., Wang, S. E., Olivares, M. G., Song, Y., Qu, S., Rinehart, C., Seidel, B., Yee, D., Arteaga, C. L., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34588 · Cited by 525
Circumventing cancer drug resistance in the era of personalized medicine
Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503
Resistance to Trastuzumab in Breast Cancer
Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 523
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.006 · Cited by 470
Pten in stromal fibroblasts suppresses mammary epithelial tumours
Trimboli, A. J., Cantemir-Stone, C. Z., Li, F., Wallace, J. A., Merchant, A. S., Creasap, N., Thompson, J. C., Caserta, E., Wang, H., Chong, J.-L., et al. (2009) · Nature · doi:10.1038/nature08486 · Cited by 507
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235
Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Spector, N. L., & Blackwell, K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 506
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 516
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
André, F., O'Regan, R. M., Özgüroğlu, M., Toi, M., Xu, B., Jérusalem, G., Masuda, N., Wilks, S. T., Arena, F. P., Isaacs, C. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70138-x · Cited by 494
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 553
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control
Georgescu, M. (2010) · Genes & Cancer · doi:10.1177/1947601911407325 · Cited by 507
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 494
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer
Murtaza, M., Dawson, S., McNamara, K. L., Rueda, O. M., Provenzano, E., Grant, J. W., Chin, S., Tsui, D. W. Y., Marass, F., Gale, D. G., et al. (2015) · Nature Communications · doi:10.1038/ncomms9760 · Cited by 486
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 480
The art and design of genetic screens: RNA interference
Boutros, M., & Ahringer, J. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2364 · Cited by 489
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5962 · Cited by 473
Luminal breast cancer: from biology to treatment
Ignatiadis, M., & Sotiriou, C. P. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.124 · Cited by 481
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
LoRusso, P. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0018 · Cited by 473
PTEN: Multiple Functions in Human Malignant Tumors
Milella, M., Falcone, I., Conciatori, F., Incani, U. C., Curatolo, A. D., Inzerilli, N., Nuzzo, C. M. A., Vaccaro, V., Vari, S., Cognetti, F., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00024 · Cited by 484
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 465
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
Jhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 465
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Burris, H. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2043-3 · Cited by 454
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.035 · Cited by 430
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Nicolini, A., Ferrari, P., & Duffy, M. J. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.010 · Cited by 442
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Carey, L., Berry, D. A., Cirrincione, C., Barry, W. T., Pitcher, B. N., Harris, L. N., Ollila, D. W., Krop, I. E., Henry, N. L., Weckstein, D. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1268 · Cited by 421
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Zotano, Á. G., Mayer, I. A., & Arteaga, C. L. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9637-x · Cited by 428
The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
Slomovitz, B. M., & Coleman, R. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0662 · Cited by 411
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Dias-Santagata, D. C., Akhavanfard, S., David, S. S., Vernovsky, K., Kuhlmann, G., Boisvert, S. L., Stubbs, H., McDermott, U., Settleman, J. E., Kwak, E. L., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000070 · Cited by 393
Targeting the androgen receptor pathway in prostate cancer
Chen, Y., Sawyers, C. L., & Scher, H. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.005 · Cited by 393
Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
Mirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D. R., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 387
Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases
Liu, S., Umezu‐Goto, M., Murph, M. M., Lu, Y., Liu, W., Zhang, F., Yu, S., Stephens, L. C., Cui, X., Murrow, G., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.027 · Cited by 385
Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications
Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 377
Targeted therapies for breast cancer
Higgins, M. J., & Baselga, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57152 · Cited by 386
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
Dutt, A., Ramos, A. H., Hammerman, P. S., Mermel, C. H., Cho, J., Sharifnia, T., Chande, A. G., Tanaka, K., Stransky, N., Greulich, H. E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020351 · Cited by 374
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
Baselga, J. M., Cortés, J., Im, S., Clark, E., Ross, G. A., Kiermaier, A. C., & Swain, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5384 · Cited by 364
The role of PTEN signaling perturbations in cancer and in targeted therapy
Keniry, M. E., & Parsons, R. E. (2008) · Oncogene · doi:10.1038/onc.2008.248 · Cited by 365
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Pernas, S., & Tolaney, S. M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833519 · Cited by 360
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients
Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
Thangue, N. B. L., & Kerr, D. J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.121 · Cited by 340
Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
O’Brien, N. A., Browne, B. C., Chow, L., Wang, Y., Ginther, C., Arboleda, J., Duffy, M. J., Crown, J. P., O’Donovan, N., & Slamon, D. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1171 · Cited by 324
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z., Teng, Q., Qin, T. L., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 338
Hereditary breast cancer: new genetic developments, new therapeutic avenues
Campeau, P. M., Foulkes, W. D., & Tischkowitz, M. D. (2008) · Human Genetics · doi:10.1007/s00439-008-0529-1 · Cited by 323
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors
Millis, S. Z., Ikeda, S., Reddy, S. B., Gatalica, Z., & Kurzrock, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0891 · Cited by 326
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 341
Resistance to chemotherapy: new treatments and novel insights into an old problem
Raguz, S., & Yagüe, E. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604510 · Cited by 319
Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genomePreprint
DeKelver, R. C., Choi, V. M., Moehle, E. A., Paschon, D. E., Hockemeyer, D. F., Meijsing, S. H., Sancak, Y., Cui, X., Steine, E. J., Miller, J. C., et al. (2010) · Genome Research · doi:10.1101/gr.106773.110 · Cited by 316
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Janne, P. A., Gray, N. S., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 312
PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality
López‐Knowles, E., O'Toole, S. A., McNeil, C. M., Millar, E. K. A., Qiu, M. R., Crea, P., Daly, R. J., Musgrove, E. A., & Sutherland, R. L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24831 · Cited by 302
Topoisomerase levels determine chemotherapy response in vitro and in vivo
Burgess, D. J., Doles, J. D., Zender, L., Xue, W., Ma, B., McCombie, W. R., Hannon, G. J., Lowe, S. W., & Hemann, M. T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803513105 · Cited by 302
Translating insights from the cancer genome into clinical practice
Chin, L., & Gray, J. W. (2008) · Nature · doi:10.1038/nature06914 · Cited by 304
PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
Prenen, H., De Schutter, J., Jacobs, B., De Roock, W., Biesmans, B., Claes, B., Lambrechts, D., Van Cutsem, E., & Tejpar, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2961 · Cited by 291
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Schlam, I. M., & Swain, S. M. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00265-1 · Cited by 308
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Waldman, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_68 · Cited by 291
Towards personalized treatment for early stage HER2-positive breast cancer
Goutsouliak, K., Veeraraghavan, J., Sethunath, V., Angelis, C. D., Osborne, C. K., Rimawi, M. F., & Schiff, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0299-9 · Cited by 285
PTEN, PIK3CA, p-AKT, and p-p70S6K Status
Esteva, F. J., Guo, H., Zhang, S., Santa-Maria, C., Stone, S., Lanchbury, J. S., Sahin, A. A., Hortobagyi, G. N., & Yu, D. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090885 · Cited by 285
A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1
Xu, Q., Jiang, Y., Yin, Y., Li, Q., He, J., Jing, Y., Qi, Y.-T., Qian, X., Li, W., Lu, J., et al. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs049 · Cited by 287
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Engelman, J. A., & Settleman, J. E. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.004 · Cited by 292
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 288

Authors: Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., Beijersbergen, R. L., Mills, G. B., van de Vijver, M. J., & Bernards, R.
Affiliations: The Netherlands Cancer Institute (NL)
The University of Texas MD Anderson Cancer Center (US)
Corresponding author: Bernards, René
ORCID: Berns, Katrien
Horlings, Hugo M.
Hennessy, Bryan T.
Hijmans, E. Marielle
Beelen, Karin
Linn, Sabine C.
Gonzalez-Angulo, Ana Maria
Hauptmann, Michael
Beijersbergen, Roderick L.
Mills, Gordon B.
Bernards, René
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2007-10
Volume: 12
Issue: 4
Pages: 395-402
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2007.08.030
OpenAlex: W2020372547
Cited by: 1,627
References: 22
Citations by year: 2026: 26 · 2025: 44 · 2024: 33 · 2023: 81 · 2022: 69 · 2021: 54 · 2020: 63 · 2019: 70 · 2018: 88 · 2017: 74 · 2016: 102 · 2015: 116 · 2014: 118 · 2013: 144 · 2012: 123
FWCI: 37.98
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2116 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Funders: National Institutes of Health
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: trastuzumab resistance, breast cancer, PI3K signaling, PTEN, PIK3CA mutation, RNAi screen, drug sensitivity, prognostic factors, HER2-positive breast cancer, treatment response prediction
MeSH terms: Trastuzumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Middle Aged, Mutation, Transduction, Genetic, Biomarkers, Tumor, Cohort Studies, Signal Transduction, Gene Expression Regulation, Neoplastic, Treatment Outcome, Disease Progression, Patient Selection, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, RNA Interference, RNA, Small Interfering, Cell Line, Tumor, PTEN Phosphohydrolase, Kaplan-Meier Estimate, Class I Phosphatidylinositol 3-Kinases, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks